Compound library / Fertility

Follitropin Alfa/Beta (Gonal-F / Follistim)

Recombinant FSH used in women for ovarian stimulation during IVF, and in men to stimulate spermatogenesis when combined with hCG.

CategoryFertility
Regulatory standingNo approved product cited
Typical routeSubcutaneous
Half-life~24-36 hours
Common dose rangeFemale stimulation: 75-300 IU/day, per protocol. Male: 75-150 IU, 2-3x/week alongside hCG.
Typical cycle lengthFemale: 8-14 day stimulation cycles. Male: months (spermatogenesis is slow).

BioHack Track models Follitropin Alfa/Beta (Gonal-F / Follistim) at a half-life of 30 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Pre-filled pens are common; powder forms reconstitute with provided diluent.

Storage

Refrigerate; some pens stable at room temperature short-term per label.

Cautions

Requires close monitoring in women (OHSS risk); male protocols require patience since spermatogenesis takes ~3 months to respond.

Track Follitropin Alfa/Beta (Gonal-F / Follistim) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Fertility

Look up the research

These open a search of each database for Follitropin Alfa/Beta (Gonal-F / Follistim) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support